CytomX Therapeutics to Announce Third Quarter 2017 Financial Results
26 Octubre 2017 - 3:26PM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will announce financial results for the third
quarter ended September 30, 2017, on November 7, 2017, after the
NASDAQ market closing.
The company will not conduct a conference call in conjunction
with this financial results press release.
About CytomX TherapeuticsCytomX Therapeutics is
a clinical-stage biopharmaceutical company with a deep and
differentiated oncology pipeline of investigational Probody™
therapeutics. Probody therapeutics are designed to exploit unique
conditions of the tumor microenvironment to more effectively
localize antibody binding and activity while limiting activity in
healthy tissues. The Company’s pipeline includes proprietary cancer
immunotherapies against clinically-validated targets, such as
PD-L1, and first-in-class Probody drug conjugates against highly
attractive targets, such as CD166 and CD71, which are considered to
be inaccessible to conventional antibody drug conjugates due to
their presence on healthy tissue. In addition to its wholly owned
programs, CytomX has strategic collaborations with AbbVie, Amgen,
Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
Media Contact: Spectrum Christine
Querncquern@spectrumscience.com202-587-2588
Investor Contact:Trout GroupPete
Rahmerprahmer@troutgroup.com 646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024